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dent hypertension associated with the use of celecoxib and non-
selective (NS) NSAIDs in a real world setting. METHODS: A
cohort study was conducted using secondary data from the GE
Centricity® Electronic Medical Record database, which contains
the medical records of 3 million patients seen by 5000 physicians
in 27 states across the US. The index date was deﬁned as the
date of the ﬁrst NS NSAID or celecoxib prescription between
January 1, 1999 and June 30, 2004. Patients were included if
they were aged 18 or older and were enrolled for at least 365
days prior to the index date. NS NSAID users were matched to
celecoxib users using propensity-based matching techniques by
a 2 : 1 ratio. Multivariate Cox proportional hazard models were
used for the analysis. RESULTS: The ﬁnal sample consisted of
51,444 patients. Among the 17,148 celecoxib users, 222 (1.3%)
had a new diagnosis of hypertension, while 446 out of the
34,296 NS NSAID users (1.3%) had a new diagnosis of hyper-
tension. The crude incidence rate for hypertension was slightly
higher for celecoxib users: 52.5 vs. 51.8 per 1000 patient per
year for celecoxib and NS NSAID users, respectively. Relative to
NS NSAID users, patients on celecoxib had a similar rate of post
exposure hypertension incidence in multivariate analyses (HR =
1.006; 95% CI: 0.856–1.181). CONCLUSION: Results from a
population-based cohort analysis of electronic medical records
suggest similar rates of incident hypertension between celecoxib
and NS NSAID users.
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OBJECTIVES: To assess the economic impact in the Mexican
Health System of a hypertensive population preventive program
(HPPP) in order to shift cardiovascular risk on the long-term.
METHODS: Costs and health beneﬁts were forecasted for the
period 2005–2025 after the implementation of a control and
detention program in hypertensive population in Mexico. Inci-
dence and prevalence data was obtained from a Mexican
National Survey (Encuesta Nacional de Salud 2000) for popula-
tion between 20–59 yrs. Preventive actions included in the
program were: opportune detention of hypertension with two
measures of arterial hypertension per year to all adult popula-
tion attended in the Mexican Health System. Secondary preven-
tion actions consisted in changes in life styles and intensive
pharmacologic treatment in patients with uncontrolled hyper-
tension. Health care costs data was obtained from the Social
Security Mexican Institute (IMSS) databases and the HPPP effec-
tiveness was taken from published literature for worldwide
similar preventive programs. Framingham tables were used to
constructed disease progression simulations and effectiveness
measures used in the assessment were the number of new cases
of patients controlled and cardiovascular events avoided. The
analysis was conducted from the health care payer’s perspective
(only direct medical costs were used). RESULTS: Through 20-
years analysis period, the total number of hypertensive cases
remained unchanged. Nevertheless, the number of new hyper-
tensive cases controlled increased in 74.8% which represented a
reduction of 6.6 millions cases uncontrolled. On the same time
horizon, the HPPP showed a decrease of 16.9% in the total
number of cardiovascular events which represented approxi-
mately 1.7 millions less complications in the Mexican Health
System. The latter could represent in the future net savings in
US$1652 millions compared to the actual scenario. CONCLU-
SION: Preventive actions included in control and detention
hypertensive programs resulted to be cost-effectiveness policies,
and showed to be cost saving strategies in the long-term.
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OBJECTIVES: To investigate differences in follow-up costs of
patients undergoing microsurgical resection, which requires hos-
pitalization, compared to steriotactic radiosurgery, an outpatient
procedure, for the treatment of vestibular schwannoma.
METHODS: Post-surgical medical utilization records and cost
data were retrospectively gathered for 82 patients undergoing
microsurgery or radiosurgery. Follow-up costs were obtained
using administrative datasets and were discounted. Thirty-one
patients did not have any follow-up care at our facilities. For
patients seeking follow-up care elsewhere utilization records
(prospectively gathered) were matched to our administrative
costs using median values. To adjust for varying lengths of
follow-up, the cohort was reduced to those having a minimum
length of follow-up of 28 months. Results were veriﬁed with 36
months of follow up. RESULTS: In the initial cohort, age and
patient location were signiﬁcantly associated with surgery type.
Radiosurgery patients tended to be older. Mean costs per month
using a six month moving average for microsurgery patients ini-
tially were high and leveled off to below $200 per month. Con-
versely mean follow-up costs for radiosurgery patients started
low and ﬂuctuated through high and low cycles, reaching as high
as $200 per month. CONCLUSIONS: Many of the radiosurgery
patients did not have follow-up at our facility so we estimated
them from surgery-related follow-up utilization. In addition,
radiosurgery is a relatively new procedure and clinicians are not
yet in agreement on a reasonable length of follow-up. Including
other health care costs for these patients and accounting for
longer follow-up length would likely increase the mean follow-
up costs of radiosurgery further relative to microsurgery. This
may make the total cost (the sum of initial and follow-up costs)
of the two procedures more comparable.
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OBJECTIVES: A decision analytic model was created to
compare the potential economic beneﬁts (cost-offsets and cost-
effectiveness) of treatment planning for peripheral arterial
disease (PAD) with either digital subtraction angiography (DSA)
and magnetic resonance angiography (MRA) technology in a
diabetic population. METHODS: The model considered degree
of stenosis, outcomes associated with a treatment plan, risk of
complications from DSA and MRA, and associated costs of
treatment. Sensitivity and speciﬁcity for DSA, considered the
